Patents by Inventor Philip Arthur Hipskind

Philip Arthur Hipskind has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110178093
    Abstract: The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: November 9, 2009
    Publication date: July 21, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jolie Anne Bastian, Julia Marie Clay, Takako Wilson (nee Takakuwa), Michelle Lee Thompson, Daniel Jon Sall, Philip Arthur Hipskind
  • Disubstituted phthalazine hedgehog pathway antagonists
    Patent number: 7981892
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: July 19, 2011
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Takako Wilson (nee Takakuwa)
  • Pyrrolidine derivatives as histamine H3 receptor antagonists
    Patent number: 7951826
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: May 31, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, Cynthia Darshini Jesudason, Richard Todd Pickard, Freddie Craig Stevens, Takako Takakuwa
  • Histamine H3 receptor antagonists, preparation and therapeutic uses
    Patent number: 7902191
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: Lisa Selsam Beavers, Robert Alan Gadski, Philip Arthur Hipskind, Cynthia Darshini Jesudason, Karen Lynn Lobb, Richard Todd Pickard, Craig William Lindsley
  • DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20110046143
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: April 1, 2009
    Publication date: February 24, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Philip Arthur Hipskind, Takako Wilson (nee Takakuwa)
  • DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS
    Publication number: 20100324048
    Abstract: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
    Type: Application
    Filed: June 15, 2010
    Publication date: December 23, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Philip Arthur Hipskind, Bharvin Kumar Patel, Takako Wilson (nee Takakuwa)
  • Substituted thiophene carboxylic amide glucagon receptor antagonists, preparation and therapeutic uses
    Patent number: 7807702
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: October 5, 2010
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Philip-Arthur Hipskind, Allie Edward Tripp, Guoxin Zhu
  • Thiazole pyrazolopyrimidines CRF1 receptor antagonists
    Publication number: 20100222339
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Application
    Filed: September 17, 2007
    Publication date: September 2, 2010
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Jason Kenneth Myers, Takako Takakuwa, James Lee Toth
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20100160406
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: March 28, 2006
    Publication date: June 24, 2010
    Inventors: Philip Arthur Hipskind, Takako Takakuwa, Cynthia Darshini Jesudason, Robert Alan Gadski, William Joseph Hornback, Richard Todd Pickard, Lisa Selsman Beavers
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20100160319
    Abstract: The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: June 28, 2006
    Publication date: June 24, 2010
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Robert Alan Gadski, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Histamine H3 receptor agents, preparation and therapeutic uses
    Patent number: 7705025
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: April 27, 2010
    Assignee: Eli Lilly and Company
    Inventors: Don Richard Finley, Terry Patrick Finn, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Takako Takakuwa
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20100048580
    Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds.
    Type: Application
    Filed: November 2, 2009
    Publication date: February 25, 2010
    Inventors: Lisa Selsam Beavers, Don Richard Finley, Terry Patrick Finn, Robert Alan Gadski, Philip Arthur Hipskind, Wiliam Joseph Hornback, Cynthia Darshini Jesudason, Richard Todd Pickard, Takako Takakuwa, Grant Mathews Vaught
  • Histamine H3 Receptor Agents, Preparation and Therapeutic Uses
    Publication number: 20100029608
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-113 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: October 13, 2009
    Publication date: February 4, 2010
    Inventors: Don Richard FINLEY, Terry Patrick FINN, Philip Arthur HIPSKIND, William Joseph HORNBACK, Cynthia Darshini Jesudason, Takako TAKAKUWA
  • THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20100022560
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Application
    Filed: September 13, 2007
    Publication date: January 28, 2010
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Shaojuan Jia, James Lee Toth
  • Imidazopyridazine compounds
    Patent number: 7612067
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: November 3, 2009
    Assignee: Eli Lilly and Company
    Inventors: Heather Janelle Barbosa, Elizabeth Aaron Collins, Chafiq Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Richard Duane Johnston, Jianliang Lu, Michael John Rupp, Takako Takakuwa, Richard Craig Thompson
  • Imidazopyridazine compounds
    Patent number: 7557103
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Grant
    Filed: April 3, 2006
    Date of Patent: July 7, 2009
    Assignee: Eli Lilly and Company
    Inventors: Elizabeth Aaron Collins, Pablo Garcia-Losada, Chafiq Hamdouchi, Philip Arthur Hipskind, Jianliang Lu, Takako Takakuwa
  • GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20090156655
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Application
    Filed: November 16, 2006
    Publication date: June 18, 2009
    Inventors: Scott Eugene Conner, Philip Arthur Hipskind, Jianke Li, Guoxin Zhu
  • HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
    Publication number: 20090048225
    Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
    Type: Application
    Filed: August 15, 2005
    Publication date: February 19, 2009
    Inventors: Don Richard Finley, Terry Patrick Finn, Philip Arthur Hipskind, William Joseph Hornback, Cynthia Darshini Jesudason, Takako Takakuwa
  • Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
    Publication number: 20080319074
    Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Application
    Filed: November 10, 2006
    Publication date: December 25, 2008
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Philip Arthur Hipskind, Jason Eric Lamar, Guoxin Zhu
  • Glucagon Receptor Antagonists, Preparation and Therapeutic Uses
    Publication number: 20080300289
    Abstract: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
    Type: Application
    Filed: November 21, 2006
    Publication date: December 4, 2008
    Inventors: Mark Donald Chappell, Scott Eugene Conner, Philip-Arthur Hipskind, Allie Edward Tripp, Guoxin Zhu